Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Debt (2018 - 2025)

Historic Total Debt for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $77577.0.

  • China SXT Pharmaceuticals' Total Debt fell 9897.42% to $77577.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $77577.0, marking a year-over-year decrease of 9897.42%. This contributed to the annual value of $105045.0 for FY2025, which is 8278.47% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Total Debt stood at $77577.0 for Q3 2025, which was down 9897.42% from $105045.0 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Debt peaked at $12.2 million during Q1 2021, and registered a low of $11404.0 during Q1 2022.
  • Its 5-year average for Total Debt is $2.7 million, with a median of $908145.0 in 2022.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Total Debt surged by 337309.82% in 2021, and later plummeted by 9990.62% in 2022.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Debt (Quarter) stood at $2.1 million in 2021, then tumbled by 43.04% to $1.2 million in 2022, then skyrocketed by 115.8% to $2.6 million in 2023, then surged by 190.55% to $7.6 million in 2024, then plummeted by 98.97% to $77577.0 in 2025.
  • Its last three reported values are $77577.0 in Q3 2025, $105045.0 for Q1 2025, and $7.6 million during Q3 2024.